

## Board Renewal / Composition Update

- ✓ **D. David Atkins to join the Board as Managing Director effective immediately.**
- ✓ **Dr Trevor Lockett and Mr Lou Panaccio to retire from the Board effective at the 2024 Annual General Meeting (AGM).**
- ✓ **Mr Otto Buttula to step down from the position of Chair, targeting prior to the end of CY'24.**
- ✓ **Ongoing discussions with potential new directors, including a new Chair.**

Transformative, predictive cancer diagnostics technology company, Rhythm Biosciences Ltd (ASX: **RHY**) (“**Rhythm**” or the “**Company**”) is pleased to provide an update on its Board Renewal and Composition initiatives.

### New Addition

Having added strong operational value to the business since commencement, in addition to successfully having completed his probationary status, the Board is delighted to welcome Dr David Atkins to the Board as Managing Director. Dr Atkins’ remuneration will remain unchanged.

### Retirements

Both, Dr Trevor Lockett and Mr Lou Panaccio, whom have been directors since before the Company’s ASX listing and having served in excess of 7 (seven) years on the Board will in the interests of renewal retire from the Board effective 20 November 2024, the day of the Company’s AGM.

### Stepping Down

Mr Otto Buttula has also expressed a desire to step down from the position of Chair after having served in excess of 5 (five) years in the position and this will be effective upon the appointment of a new Board Member and Chair, which the Company is targeting to achieve prior to the end of the calendar year.

### Rhythm Chairman, Otto Buttula, commented:

*“As a Board, we are delighted to appoint David as Managing Director of the Company. Having observed David in the role of CEO since May, the Board has admired his leadership and team building skills, his strong and tireless commitment and tenacious approach to building out Rhythm’s protected intellectual property portfolio. We believe David has displayed the right approach to rebuilding the Company and restoring shareholder value, initially through the impending launch of ColoSTAT® in what we believe to be a more robust and commercially attractive product offering.*

*On behalf of the Company, whilst their retirement is not effective until the AGM, I would also like to gratefully acknowledge Dr Lockett and Mr Panaccio for their service and contribution to the Company since its’ inception, both were instrumental in the early stages, respectively as technology advisor and professional ASX Board member, over the past 7 plus years. Despite retiring, Dr Lockett has offered to continue to provide support on an as required, consultancy basis. The Company wishes both Dr Lockett and Mr Panaccio well in their future endeavours.”*

- ENDS -

**Rhythm Biosciences Ltd**  
ACN 619 459 335  
ASX: RHY

[www.rhythmbio.com](http://www.rhythmbio.com)

**Australian Registered Address**  
Bio21 Molecular Science & Biotechnology Institute  
30 Flemington Road  
Parkville VIC 3010 Australia

**T** +61 3 8256 2880  
**E** [info@rhythmbio.com](mailto:info@rhythmbio.com)

### Directors

Otto Buttula	Non-Executive Chairman
Sue MacLeman	Non-Executive Deputy Chair
David Atkins	Managing Director & CEO
Trevor Lockett	Non-Executive Director
Louis Panaccio	Non-Executive Director

**Authorised for release by the Board.**

**For further information contact us via [investor@rhythmbio.com](mailto:investor@rhythmbio.com):**

<b>Dr. David Atkins</b> Chief Executive Officer & Managing Director	<b>Ms. Andrea Steele</b> Jt. Company Secretary
--	---

**About Rhythm Biosciences**

Rhythm Biosciences Ltd (ASX: RHY) is an Australian innovative, medical diagnostics company aimed at delivering simple, affordable blood tests for accurate and early detection of cancers. Rhythm is focused on improving patient outcomes through detection at the earliest possible stage, reducing the global burden of cancer and saving lives.

Rhythm Biosciences is committed to working with likeminded global partners to achieve commercialisation and distribution of these simple solutions.

The company was founded in 2017 and is headquartered in Melbourne, Australia. For more information, visit [rhythmbio.com](http://rhythmbio.com) and follow the company on LinkedIn and X.

For personal use only